Avectas announces the appointment of Dr. Ann Brady as Chief Business Officer DUBLIN, Ireland and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Avectas, a cell engineering technology business, announces the appointment of Dr. Ann Brady as Chief Business Officer (CBO)...

Avectas Launches the Solupore® Platform for the Clinical Manufacturing of Next-Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality DUBLIN, Ireland and CAMBRIDGE, Mass., Jan. 16, 2023 (GLOBE NEWSWIRE) -- Avectas, a cell engineering technology leader, announces the launch of the Solupore platform at the Advanced Therapies Week,...

Avectas, CCRM and OmniaBio Expand their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE® Technology DUBLIN, Ireland and TORONTO, Canada, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avectas, a cell engineering technology business and CCRM, with its subsidiary OmniaBio Inc., a CDMO that enables the...